You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
仙琚製藥(002332.SZ):收到地塞米松磷酸鈉注射液補充申請受理通知書
格隆匯 04-06 16:23

格隆匯 4 月 6日丨仙琚製藥(002332.SZ)公佈,公司於近日收到國家藥品監督管理局下發的地塞米松磷酸鈉注射液補充申請受理通知書。

據悉,地塞米松磷酸鈉注射液最早由 MERCK 公司研發,1959 年經 FDA 批准上市。地塞米松磷酸鈉注射液主要用於過敏性與自身免疫性炎症性疾病。多用於結締組織病、活動性風濕病、類風濕性關節炎、紅斑狼瘡、嚴重支氣管哮喘、嚴重皮炎、潰瘍性結腸炎、急性白血病等,也用於某些嚴重感染及中毒、惡性淋巴瘤的綜合治療。

公司已持有地塞米松磷酸鈉注射液 1ml:2mg 、1ml:5mg 等規格的批准文號,目前產品執行標準《中國藥典》2020 年版二部。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account